BASJVETRES

Research Article

Proceeding of 8th International Scientific Conference, College of Veterinary Medicine University of Basrah, Dec. 7-8, 2022,Iraq.

BASRAH JOURNAL OF VETERINARY RESEARCH, 2022, 21(S1):75-83 https://bjvr.uobasrah.edu.ig/

Effect of combination of metformin with B12 and folic acid on lipid profile and levels of homocysteine in adult male rabbits

Eman Aboud Al-Masoudi, Nawras A. Alwan, Hadeer Qasim, Zanib Imad

Department of Physiology, Pharmacology and Biochemistry. College of Veterinary Medicine, University of Basrah. Corresponding Author Email Address: <u>Emanalmasoudil2@gmail.com</u> ORCID ID:1809-5381-0001-0000 Accepted: Nov. 2022

Abstract

The present study aims to evaluate the effects of metformin in combination with vitamin B12 and folic acid on lipid profiles and serum homocysteine levels in male rabbits. The study included twenty-four male rabbits that weighed (1.5-2 kg), and were divided randomly into four groups (six rabbits/group). The control first group was administrated (5 ml) of distilled water; The second group was given metformin (125g/kg B.W) plus vitamin B12 (500 µg/kg B.W) daily, the third group was given metformin (125g/kg B.W) plus folic acid (5g/kg B.W) daily and the fourth group was given metformin (125g/kg B.W), folic acid (5g/kg B.W) and vitamin B12 (500 µg/kg B.W) daily, the rabbits were followed up for one month. The results revealed a decrease in the final body weight and body weight gain in all treated groups as compared to the control group. The homocysteine parameter decreases significantly in the second group which was given metformin and B12 and the third group was given metformin in combination with folic acid as compared with the control group and group four. It showed a significant decrease in the fourth group (metformin + folic acid + vitamin B12) compared with the second and third groups also the glucose level increased significantly in group three compared to group second, fourth, and control group. The results showed that serum cholesterol and TG have decreased in G2 and G3 while an increase in G4 as compared with the control group, and the HDL was decreased in G2 and G4 compared with control and G3 groups. While the results of LDL and VLDL were increased in G3 compared the control and G4 with G2 and group.

Key words: metformin, vitamin B12, folic acid, lipid.

Introduction

Vitamin B12 is a vital nutrient for health. It plays an important role in the functioning of the brain and nervous system, and the formation of red blood cells. In addition to vitamin B12 deficiency may anemia. increase the severity of peripheral neuropathy in patients with type II Diabetic Mellitus (T2DM) (1). Furthermore, because vitamin B12 participates in the most important pathway of homocysteine (Hcy) metabolism, a reduction in vitamin B12 would increase plasma concentrations of which strongly Hcy. is linked to cardiovascular disease in patients with T2DM (2) and PCOS (3). Folic acid, a water-soluble vitamin B, has recently gained considerable attention because of its great potential to prevent many disorders through supplementation for the general population, folic acid was repeatedly reported to improve endothelial dysfunction in various clinical conditions, although the mechanisms of this beneficial effect are not fully understood, it seems that folate (a main circulating metabolite of folic acid in plasma is 5MeTHF) acts through at least four mechanisms in atherosclerosis: (i) indirectly, to decrease homocysteine level and ensure optimal functioning of the methylation

cycle, (ii) directly, produce antioxidant effects, (iii) interact with enzyme endothelial nitric oxide synthase (eNOS), and (iv)affect cofactor bioavailability of nitric oxide (4). For folic acid it has been found: (a) revert dysfunction of eNOS (5) (b) influence on postprandial endothelial dysfunction (6) (c) improve endothelial function in coronary artery disease by reduction of intracellular (7) (d) to inhibit intimal hyperplasia induced by a high-homocysteine diet in a rat carotid endarterectomy model (8) (e) to reverse endocardial endothelial dysfunction in homocysteinemia hypertensive rats (9) and (f) anti- arrhythmia effects after reperfusion injury in rat heart (10). The present study aims to examine the evaluation effects of metformin in combination with vitamin B12 and folic acid on the level of lipid profile and homocysteine in male rabbits.

Materials and Methods

Experimental animals: The present study was carried out at the College of Veterinary Medicine/ University of Basrah. Twenty-four adult male rabbits were used for this study. The animals were kept in the animal house for acclimatization fourteen days

before the beginning of the experiments. The animals were maintained under optimum conditions (25+2 °C) and (12/12 hours light/dark) cycle throughout the study, with standard pellets and tap water.

Experimental design: The experimental animals were included in this study: Twenty-four adult male rabbits are randomly divided into four groups as the following:

Group1 (control): 6 adult male rabbits orally administered distilled water (15 ml/animal) by gavage daily for thirty days.

Group2 (M+FA): 6 adult male rabbits were orally administration metformin hydrochloride (125 mg/kg BW) and folic acid (5mg/kg BW) dissolved in 15ml distilled water by gavage daily for thirty days.

Group 3 (M+B12): 6 adult male rabbits were orally administration metformin hydrochloride (125mg/kg BW) dissolved in 15ml distilled water and vitamin B12 (500 μg/kg BW) by gavage daily for thirty days.

Group4 (M+FA+B12): 6 adult male rabbits were orally administration metformin hydrochloride (125mg/kg BW) dissolved in 15ml distilled water plus folic acid (5mg/kg BW) and vitamin B12(500µg/kg BW) by gavage daily for thirty days.

Collected blood samples from the heart by cardiac puncture before sacrificed animals using a sterile 5 cc syringe dropped into a tubeless anticoagulant plain and blood serum was isolated from the blood by centrifugation at 3000 rpm for 15 min. They are separated in Eppendorf tubes and stored at -20°C until a biochemical analysis is performed.

Studied parameters:

Serum homocysteine level: It measured by Albean laboratory by special kits.

Total cholesterol measurement: Serum total cholesterol was enzymatically measurement by using a linear chemical kit (BIO-ABO S.A/CHOD-PAP, France) (11).

Serum triglyceride measurement: The concentration of serum triglyceride was measured by using a special chemical kit (SYRBIO/GPO-PAP/ Syria) based on (12).

Determination of serum lipoprotein cholesterol: Three types of lipoprotein cholesterol measured by the following:

SerumHigh-DensityLipoproteinCholesterol (HDL-C):The principal role ofHDL in the lipid metabolism is the uptake

and transport of cholesterol from peripheral tissues to the liver through a process known as revers cholesterol transport (11).

Serum Low-Density Lipoprotein Cholesterol (LDL-C): Serum LDL concentration can be calculated by the following equation (13). LDL = TC - (HDL+TG/5)

Serum very Low-Density Lipoprotein (VLDL): Serum VLDL concentration was calculated by dividing serum TG/5 (14). VLDL=TG/5

Result:

1- Effect of their combination M, FA and B12 on body weights and body weight gain of male rabbits: There were no significant changes in initial BW between all groups. The results in table (1) revealed significant (p< 0.05) decrease in the final BW in all treated groups compared with control group (G1).

2- Effect of combination M, FA and B12 on serum Homocysteine and glucose concentrations of male rabbits: Table (2) showed significant (p<0.05) increase in the concentration of Hyc in G2, G3 and G4 compared with control group. While there is significant (p<0.05) decrease in G4 compared with G2 and G3. The results revealed significant (p<0.05) decrease in serum glucose concentrations in G2 and increased significantly (p<0.05) in G3 and G4 compared with control group.

3- Effect of M, FA, B12 and their combination on serum lipid profile in male rabbits: In table (3) the results of TC showed significant (p<0.05) increase in the G4 compared with control and other treated groups while there is significant (p<0.05)decrease in G2 and G3. The results of TG concentration revealed a significant (p < 0.05) decrease in G2 and G3 compare to the control group. Serum HDL concentrations significantly (p<0.05) decreased in G2 and G4 compared to the control group and G3. While serum LDL concentrations increased significantly in G3, G4 more than other treated groups and compared to the control group. Also, table (3) revealed the significant (p<0.05) increased in serum VLDL in G4 compared to G2, G3 and control group.

| Groups | Initial BW | Final BW | BW gain |
|---------------|-------------------------|-------------------------------|----------------------------|
| G1 (control) | 1.65±0.23 ^{Aa} | 1.82±0.09 ^{Aa} | $0.17 \pm 0.14^{\text{A}}$ |
| G2 (M+FA) | 1.67 ± 0.05^{Aa} | $1.45{\pm}0.17^{\mathrm{Ba}}$ | -0.22 ± 0.12^{C} |
| G3 (M+B12) | 1.60±0.73 ^{Aa} | $1.46{\pm}0.18^{Ba}$ | -0.16±0.55 ^A |
| G4 (M+FA+B12) | 1.61±0.12 ^{Aa} | $1.17{\pm}0.15^{Ca}$ | -0.44 ± 0.03^{B} |
| LSD | N.S | 0.27 | 0.20 |

Table (1) Effect of M, FA, B₁₂ and their combination on body weights and body weight gain of male rabbits (M±SD):

Values are expressed in capital letters mean significant differences at (p< 0.05).

Table (2) Effect of M, FA, B12 and their combination on serum Homocystine and glucose concentrations of male rabbits:

| Groups | Hyc | glucose | |
|---------------|--------------------------|-------------------------------|--|
| G1 (control) | 4.02 ± 0.38^{D} | 85.95±1.88 ^C | |
| G2 (M+FA) | $11.90{\pm}0.34^{\rm A}$ | 78.16 ± 1.16^{D} | |
| G3 (M+B12) | $11.02{\pm}0.40^{B}$ | 12.05±6.63 ^A 1 | |
| G4 (M+FA+B12) | $7.05 \pm 1.02^{\circ}$ | $90.64 \pm 2.55^{\mathrm{B}}$ | |
| LSD | 0.78 | 4.27 | |

Values are expressed in capital letters mean significant differences at (p< 0.05).

Table (3) Effect of combination of M, FA, B12 and on serum lipid profile in male rabbits:

| Groups | ТС | TG | HDL | LDL | VLDL |
|--------------|--------------------------|--------------------------------|-------------------------|--------------------------|--------------------------|
| G1 (control) | 109.60±7.25 ^B | 105.20±6.05 ^c | 27.71±1.72 ^A | 77.08 ± 4.74^{B} | 26.67 ± 0.78^{A} |
| G2 (M+FA) | 96.54 ± 7.19^{B} | $95.91{\pm}5.14^{\rm B}$ | $21.44{\pm}1.03^{B}$ | $80.83{\pm}1.98^{\rm B}$ | 2.64 ^A ±26.83 |
| G3 (M+B12) | 95.05 ± 1.95^{B} | 96.17 ± 3.29^{B} | 27.35±1.35 ^A | 89.59±2.11 ^A | 31.03 ± 1.34^{B} |
| G4(M+FA+B12) | 123.01 ± 4.24^{A} | $119.95 \pm 7.55^{\mathrm{A}}$ | 21.20 ± 0.99^{B} | 87.13 ± 5.08^{A} | 31.70 ± 1.74^{B} |
| LSD | 13.07 | 9.03 | 5.91 | 5.44 | 4.02 |

Values are expressed in capital letters mean significant differences at (p< 0.05) levels(M±SD).

Discussion:

Homocysteine is an essential amino acid required for the growth of cells and tissues in the human body. Vitamin B6, B12 and folate are essential factors in the processes of synthesis of homocysteine. In the human body, the Hcy is an essential amino acid required for the growth of cells and tissues (15). The results of BW and BW gain showed decreased as compared with control group. Despite the well-known glucoselowering effects of metformin, more recent clinical interest lies in its potential as a weight-loss drug. Here, we discuss potential mechanisms by which metformin reduces appetite and opposes unfavorable lipid storage in peripheral tissues. Recent findings: Many individuals struggle to maintain clinically relevant weight loss from lifestyle and bariatric surgical interventions. Long-term follow-up from the Diabetes Prevention Program demonstrates that metformin leads to permanent weight loss and that reducing food intake with metformin is the primary mechanism for weight loss. Although the effect of metformin on appetite is likely to be multifactorial, changes in hypothalamic physiology, including sensitivity to leptin and insulin, have been documented (16). This study showed a significant decrease in Hcy levels seen in the B-group vitamin and folic acid plus metformin (G4). The only source of Hcy comes from the methionine in dietary proteins, which are mainly of animal origin. Homocysteine may undergo remethylation to methionine or transsulphuration to cystathionin and cysteine. Plasma homocysteine levels are influenced by several variables including smoking,

folate status, and some drugs such as methotrexate, nitrous oxide, metformin, or azaribine, that reacts with folic acid, vitamin respectively can B12 or B6 cause hyperhomocysteinemia. Ten percent of the risk of coronary artery disease in the general population is attributable to an increase in Hcy levels which may be due to vascular damage and alteration in the coagulation process (15). This study showed a significant decrease in Hcy levels was seen in the B-group vitamin and the folic acid plus metformin (G4) the agreement of the results with Wulffele et al. (17). The current study showed a significant increase in serum Hcy in group vitamin B12 plus metformin (G2, G3, and G4). The mechanisms by which drugs alter the plasma Hcy level vary. Any drug, such as methotrexate, nitrous oxide, metformin, or azaribine that reacts with folic acid, vitamin B12, or B6 can cause hyperhomocysteinemia (18).Interference with vitamin absorption from the gut may lead to increased plasma Hcy levels (19). The results also showed that serum cholesterol and TG were decreased in G2 and G3 and increased in G4 as compared with the control group, and the HDL was increased in all groups except G4 compared with the control group. Also, the result showed that LDL was increased in G3 and G4 as compared with the control group. This effect on lipid profile may be a due imbalance between normal rabbits of fat metabolism secretion (20).Metformin monotherapy significantly improves dyslipidemia in statin-naive subjects with T2DM. Its lipid-modifying effect may be

coffee consumption, renal function, vitB12,

attributed to insulin sensitivity, irreversible reduction of LDL-C glucose, and weight loss. In practice, people with dyslipidemia who are not eligible to receive lipidlowering agents may benefit from treatment with metformin. Furthermore, previous studies suggest a synergistic effect between metformin and statins, which may further reduce cardiovascular events in high-risk individuals. Overall, metformin is a safe and effective approach to relieving dyslipidemia in people newly diagnosed with T2DM (21; 22).

Conclusion: Administration of B-group vitamins and folic acid effective in reducing elevated Hcy levels in male rabbits undergoing short-term metformin therapy.

conflict of Interest

The author(s) declared that there is no conflict of interest.

References:

1-Viswa, S.; Sivasakthi, K.; Monitta Robinson D. and Hariharan, V. (2020). Metformin Induced Vitamin B12Deficiency amongType 2 Diabetes Mellitus Patients. *Indian J. of Pharm. Pract, 13* (1) :1-6.

2-Hoogeveen, E.K.; Kostense, P.J.; Beks, P.J.; Mackaay, A.J. and Jakobs, C. (1998). Hyperhomocysteinemia Is Associated with an Increased Risk of Cardiovascular Disease, Especially in Non–Insulin-Dependent Diabetes Mellitus A Population-Based Study. *Arterioscler. Thromb. Vasc. Biol.; 18:* 133–138. 3-Vrbíková, J.; Bičíková, M.; Tallová, J.; Hill, M. and Stárka, L. (2002). Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. *Exp. Clin. Endocrinol. Diab.; 110*: 74–76.

4-Stanger, O. (2002). Physiology of folic acid in health and disease. Current Drug Metabolism. Pp.: 1-13.

5-Stroess, E.S.; Van Faassen, E.E.; Yo, M.; Martasek, P.; Boer, P. and Govers, R. (2000). Folic acid reverts dysfunction of endothelial nitric oxide synthase. *Circulation Res.; 86:* 1129-34.

6-Wilmink, H.W.; Stroess, E.S.; Erkelens, W.D.; Gerritsen, W.B.; Wever, R. and Banga, J.D. (2000). Influence of folic acid on postprandial endothelial dysfunction. *Arterioscler Thromb Vasc. Biol.; 20*: 185-8.

7-Doshi, S.N.; McDowell, I.F.; Moat, S.J.; Lang, D.; Newcombe, R.G. and Kredan, M.B. (2001). Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? *Arterioscler Thromb Vasc. Biol.;21:* 1196-1202.

8-Smith, T.P.; Cruz, C.P.; Brown, A.T.; Eidt, J.F. and Moursi, M.M. (2001). Folate supplementation inhibits intimal hyperplasia induced by a high-homocysteine diet in a rat carotid endarterectomy model. *J. Vasc. Surg.; 34:* 474-81.

9-Miller, A.; Mujumdar, V.; Palmer, L.; Bower, J.D. and Tyagi, S.C. (2002). Reversal of endocardial endothelial dysfunction by folic acid in Al-Masoudi et al.,

homocysteinemic hypertensive rats. Am. J. Hypertens.; 15(2 Pt 1): 157-63.

10-Adameova, A. Shah, A.K. and Dhalla, N. S. (2020). Role of Oxidative Stress in the Genesis of Ventricular Arrhythmias. *Inter. J. of Molec. Sci.21*(12),; 4200.

11-Tietz, N.W. (2006). Clinical guide to laboratory test. 4th ed. Publ. U.S.; 638-9ET: 1062-1065.

12-Stein, E.A. (1987). Lipids, lipoproteins and apolipoproteins. In :Tietiz, N.W. Fundamentals of clinical chemistry. 3rd ed. Philadelphia: WB. Saunders. Pp.: 488.

13-Ram, A. (1996). Effect of Pulmago zeylanica in hyperlipidemic rabbits, it modification by vitamin E. *Indian. J. Pharmacol.; 28*:161-166.

14-Friedwald, W.T.; Levy, R.I. and Fredrickson, D.S. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin. Chem.; 18*:499–502.

15-Boushey, C.J.; Beresford, S.A.; Omenn, G.S. and Motulsky A.G. (1995). A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *J.A.M.A.; 274*:1049-1057.

16-Steven, M.K. and Sangeeta, K.R. (2014). Effects of metformin on weight loss: potential mechanisms. Wolters Kluwer Health | Lippincott Williams & Wilkins. Pp.:1-7. 17-Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B. (2003). Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. *J. Intern. Med.;* 254: 455–463.

18-de la Calle, E.E.; Rodriguez, C.; Walker-Thurmond, K. and Thun M. J. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 24;348(17):1625-38

19-Desouza, C.; Keebler, M.; McNamara, D.B. and Fonseca, V. (2002). Drugs affecting homocysteine metabolism: impact on cardiovascular risk. *Drugs; 62*:605–616.

20-Owen, M.D.; Baker, B.C.; Scott, El.M. and Forbes, K. (2021). Interaction between Metformin, Folate and Vitamin B12 and the Potential Impact on Fetal Growth and Long-Term Metabolic Health in Diabetic Pregnancies. *Int. J. Mol. Sci.*; 22(11): 5759.

21-Lin, S. H.; Cheng, P.Ch.; Tu, Sh. T.; Hsu, Sh. R.; Cheng, Y. Ch. and Liu, Y. H. (2018). Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed type 2 diabetes mellitus: a cohort study. *J. of Environment Research. Peer J.* 6:e4578 https://doi.org/10.7717/peerj.4578.

22-Weng, Sh.; Luo, Y.; Zhang, Z.; Su, X. and Peng, D. (2020) .Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials. *Endocrine*. 67: 305–317.

Eman Aboud Al-Masoudi, Nawras A. Alwan, Hadeer Qasim, Zanib Imad ايمان عبود المسعودي، نورس عبدالله علوان، هدير قاسم، زينب عماد

كلية الطب البيطري، جامعة البصرة

الخلاصة

الهدف من هذه الدراسة هو تقييم تأثير تركيبة الميتفورمين مع فيتامين ب 12 وحمض الفوليك على ملامح الدهون ومستوى الهوموسيستين في الدم في ذكور الأرانب. اشتملت الدراسة على أربعة و عشرين أرنبأ ذكور بوزن (5.1-2 كجم)، مقسمة إلى أربع مجموعات (ستة أرانب / مجموعة). تم استخدام مجموعة التحكم أولاً (5 مل) من الماء المقطر. المجموعة الثانية أعطيت الميتفورمين (125 جم / كجم من وزن الجسم) بالإضافة إلى فيتامين ب 12 (500 ميكروجرام / كجم من وزن الجسم) يوميًا، المجموعة الثالثة أعطيت الميتفورمين (125 جم / كجم من وزن الجسم) زائد حمض الفوليك (5 جم / كجم من وزن الجسم) يوميًا والمجموعة الثالثة أعطيت الميتفورمين (125 جم / كجم من وزن الجسم) يوميًا، وتمت منابعة هذه الأرانب لمدة شهر. وزن الجسم) يوميًا والمجموعة الثالثة أعطيت الميتفورمين (125 جم / كجم من وزن الجسم) زائد حمض الفوليك (5 جم / كجم من وزن الجسم) يوميًا والمجموعة الثالثة أعطيت الميتفورين (125 جم / كجم من وزن الجسم) يوميًا، وتمت متابعة هذه الأرانب لمدة شهر. جم / كجم من وزن الجسم) وفيتامين ب 12 (500 مليغرام / كجم من وزن الجسم) يوميًا، وتمت متابعة هذه الأرانب لمدة شهر. أظهرت النتائج انخفاضًا في وزن الجسم النهائي ووزن الجسم المكنسب في جميع المجموعات المعالجة مقارنة بمجموعة أظهرت النتائج المعامي وفيتامين ب 12 (500 مليغرام / كجم من وزن الجسم) يوميًا، وتمت متابعة هذه الأرانب لمدة شهر. ويند النتائج انخفاضًا في وزن الجسم النهائي ووزن الجسم المكنسب في جميع المجموعات المعالجة مقارنة بمجموعة أظهرت النتائج المعامي وفيتامين بشكل كبير في المجموعة السيطرة والمجموعة الميتفررمين و 128 والمجموعة الثالثة الميون تركيبة الميتفورمين مع حمض الفوليك مقارنة مع المجموعة السيطرة والمجموعة الرابعة. كما ظهر مستوى الجلوكوز وزيادة معنويا في المجموعة الرابعة (124 + M) مقارنة بالمجموعة السيطرة والمجموعة الرابعة. والثالثة بينما أظهر مستوى الجلوكوز وزيادة معنويا في المجموعة الرابعة (25 و10 بينما زاد في 64 مقاوم موعة السيطرة، وانخفض مستوى الجلوكوز وزيادة معنويا في المجموعة الرابعة مع مجموعة السيطرة و30. في دين زادت مستوية الدهون الخمارة للكوليسترول في الدم والكليسريو الثلائي انخفض في 62 و30 وينما زاد في 64 مقارنة بمجموعة السيطرة، وانخفض مستوى الدهون الجيوة معنوية المحارة مع 629 موارية مع مجموعة السيطرة و30. في زادت مستو

الكلمات المفتاحية: ميتفورمين، فيتامين ب 12, حامض الفوليك، دهون.